Juvenile Idiopathic Arthritis Clinical Trial
Official title:
Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (Pharmachild) Treated With Biologic Agents and/or Methotrexate. A PRINTO/PRES Registry
BACKGROUND: Juvenile idiopathic arthritis (JIA) is the most common chronic paediatric
rheumatic disease (PRD) and an important cause of short and long-term disability. Although
none of the available drugs for JIA has a curative potential, prognosis has greatly improved
as a result of substantial progress in disease management. The therapeutic treatment of
children with JIA encompasses the use of NSAIDs and intra-articular steroid injections. In
those patients not responding to NSAIDs, methotrexate (MTX) has become the disease modifying
anti-rheumatic drug (DMARD) of first choice worldwide. For children not responding to MTX,
biologic agents recently have become treatment options.
PATIENTS AND METHODS: 3-10 year observation study related to children with JIA undergoing
treatment with MTX or biologic agents with the following objectives:
1. To create a long-term observational registry of a large population of prevalent and
incident cases.
2. Use the accumulating data in the registry to conduct (i) a pharmacovigilance/safety
study (primary endpoint) and (ii) estimate effectiveness (frequency and magnitude of
response, disease activity over time inhibition or slowing of joint erosions and other
radiological evidence of disease progression,), and (iii) estimate adherence to the
various treatment regimens. Data from the registry will be used to compare safety and
effectiveness profiles amongst the patient cohorts.
3. To identify clinical and laboratory predictors of safety, response to therapy, including
remission This project has retrospective (first 3 years) and prospective components (up
to 10 years) and will be conducted by the participating centres of the more than 50
countries belonging to the Paediatric Rheumatology INternational Trials Organisation
(PRINTO certified ISO 9001-2008, www.printo.it), or the Pediatric Rheumatology European
Society (PRES at www.pres.org.uk). The main role of these organisations is to provide a
scientific basis for current treatments of paediatric rheumatic diseases.
The overall hypothesis to be tested is:
• Biologic agents ± MTX agents are able to maintain an acceptable safety profile in the long
term in children with different JIA categories while achieving clinical remission and
prevent/stop joint erosion development over time.
The overall aims are to establish the long term safety of biologic agents and MTX, and their
relative effectiveness in children with JIA who need treatment with second line agents.
Study Design This is a 3-10 year, international, multicentre, observational, safety and
efficacy (response, joint erosion, damage, and treatment adherence) study aimed at collecting
prospective safety, tolerability, efficacy, and treatment adherence information on JIA
subjects exposed to any biologic agents and MTX, according to local standard of practice.
This is a non-interventional study, where the medicinal products are prescribed as per the
investigator's decision. The assignment of the subject to a particular therapeutic strategy
is not decided in advance by the study protocol, but falls within current practice and the
prescription of the medicine is clearly separated from the decision to include the subject in
the study. No additional diagnostic or monitoring procedures shall be applied to the subjects
and epidemiological methods will be used for the analysis of collected data.
Duration and treatment will be as per investigator's decision. The nature and frequency of
subjects' visits to the investigator's site will be determined only by the investigator,
according to his/her judgment on the basis of the clinical evolution of the subject.
The duration of the study is expected to be at least 3 years from initiation of the first
site and may be continued beyond if adequate funding is be available.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02776735 -
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
|
Phase 2 | |
| Active, not recruiting |
NCT03092427 -
Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)
|
N/A | |
| Not yet recruiting |
NCT05545098 -
MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA
|
||
| Not yet recruiting |
NCT03833609 -
Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis
|
N/A | |
| Completed |
NCT02524340 -
Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference
|
||
| Recruiting |
NCT01434082 -
Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis
|
N/A | |
| Completed |
NCT04671524 -
The Effect of Improvement in Function on Foot Pressure, Balance and Gait in Children With Upper Extremity Affected
|
N/A | |
| Recruiting |
NCT04167488 -
Assessment of Physical Activity Among Juvenile Idiopathic Arthritis Children Performed With Actigraphy
|
N/A | |
| Recruiting |
NCT04205500 -
Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis
|
N/A | |
| Terminated |
NCT01694264 -
Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα
|
Phase 3 | |
| Completed |
NCT02824978 -
Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?
|
||
| Active, not recruiting |
NCT03841357 -
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
|
Phase 3 | |
| Completed |
NCT03833271 -
The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary
|
Early Phase 1 | |
| Completed |
NCT01455701 -
A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 1 | |
| Completed |
NCT05031104 -
Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis
|
N/A | |
| Not yet recruiting |
NCT01436019 -
Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis
|
N/A | |
| Recruiting |
NCT05609630 -
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
|
Phase 3 | |
| Recruiting |
NCT05696340 -
Access to Pediatric Rheumatology Centers for JIA Patients: Factors Associated With Time to Access Pediatric Rheumatology Centers
|
||
| Recruiting |
NCT05545839 -
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
|
N/A | |
| Completed |
NCT05436301 -
Turkish Validity and Reliability of Pain Catastrophizing Scale-Child (PCS-C)
|